Alzheimer disease trials in Brazil

In Brazil 14 Also abroad 815

14 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Brasília, Campinas, Curitiba, Porto Alegre, Rio de Janeiro, São Paulo
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
No phaseTaking people
InRAD Observational Study
Where
São Paulo
Age
18 years and over
People
50,000 worldwide
Run by
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700
Phase 3Taking people
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Where
Porto Alegre
Age
55 years to 80 years
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07717411
Phase 2/3Taking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Brasília, Curitiba, Joinville, Passo Fundo, Porto Alegre, Rio de Janeiro, São Bernardo do Campo, São Paulo
Age
55 years to 95 years
People
1,074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
Phase 3Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Brasília, Curitiba, Passo Fundo, Porto Alegre, Rio de Janeiro, São Bernardo do Campo, São Paulo
Age
55 years to 95 years
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Brasília, Rio de Janeiro, São Paulo
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Aracaju, Brasília, Curitiba, São Paulo
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
No phaseTaking people
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
Where
Manaus
Age
65 years and over
People
150
Run by
Getúlio Vargas University Hospital
See details and how to joinNCT07391436
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Curitiba, Joinville, Maringá, Porto Alegre, São Bernardo do Campo, São Paulo
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Brasília, Rio de Janeiro, São Paulo
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Brasília, Campinas, Curitiba, Porto Alegre, Rio de Janeiro, São Paulo
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Fortaleza, Maringá, Rio de Janeiro, São Paulo
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
São Paulo
Age
18 years and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
No phaseTaking people
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
Where
Rio de Janeiro
Age
50 years and over
People
40
Run by
Universidade Federal do Rio de Janeiro
See details and how to joinNCT06733714